10x Genomics (TXG) Expands Fred Hutch Cancer Work, Is The Valuation Case Still Convincing?

Simply Wall St.10-18 06:37

10x Genomics (TXG) is back in focus after a new multi project research tie up with Fred Hutchinson Cancer Center, linking its single cell platforms more directly to potential cancer diagnostic use. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2676523936?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice2-card/1789016329041","is_english":true,"pubTime":"2026-10-18 06:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2676523936","market":"us","top_or_hot":-1,"title":"10x Genomics (TXG) Expands Fred Hutch Cancer Work, Is The Valuation Case Still Convincing?","media":"Simply Wall St.","content":"<div>\n<p>10x Genomics (TXG) is back in focus after a new multi project research tie up with Fred Hutchinson Cancer Center, linking its single cell platforms more directly to potential cancer diagnostic use. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-txg/10x-genomics/news/10x-genomics-txg-expands-fred-hutch-cancer-work-is-the-valua\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10x Genomics (TXG) Expands Fred Hutch Cancer Work, Is The Valuation Case Still Convincing?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10x Genomics (TXG) Expands Fred Hutch Cancer Work, Is The Valuation Case Still Convincing?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-18 06:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-txg/10x-genomics/news/10x-genomics-txg-expands-fred-hutch-cancer-work-is-the-valua><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>10x Genomics (TXG) is back in focus after a new multi project research tie up with Fred Hutchinson Cancer Center, linking its single cell platforms more directly to potential cancer diagnostic use. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-txg/10x-genomics/news/10x-genomics-txg-expands-fred-hutch-cancer-work-is-the-valua\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ARKG","symbol_name":"ARK Genomic Revolution ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-txg/10x-genomics/news/10x-genomics-txg-expands-fred-hutch-cancer-work-is-the-valua","article_id":"2676523936","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice2-card/1789016329041"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-txg/10x-genomics/news/10x-genomics-txg-expands-fred-hutch-cancer-work-is-the-valua","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2676523936","pubTimestamp":1792276627,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"10x Genomics (TXG) is back in focus after a new multi project research tie up with Fred Hutchinson Cancer Center, linking its single cell platforms more directly to potential cancer diagnostic use.\nRecent trading tells a contrasting story. The share price has slid 13.4% over the past week and 9.2% over the last month, even after a 59.7% 90 day share price return and a very large 1 year total shareholder return, as investors weigh 10x Genomics’ clinical progress against concerns about revenue...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"ARKG":"ARK Genomic Revolution ETF","BK4588":"碎股","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4585":"ETF&股票定投概念","LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","TXG":"10x Genomics, Inc.","BK4548":"巴美列捷福持仓","FMED":"Fidelity Disruptive Medicine ETF","BK4121":"生命科学工具和服务"},"translate_title":"10x Genomics (TXG) 扩展 Fred Hutch 癌症工作，估值案例是否仍然令人信服？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FMED":0.6,"TXG":1.5,"ARKG":0.6},"content_text":"10x Genomics (TXG) is back in focus after a new multi project research tie up with Fred Hutchinson Cancer Center, linking its single cell platforms more directly to potential cancer diagnostic use. Recent trading tells a contrasting story. The share price has slid 13.4% over the past week and 9.2% over the last month, even after a 59.7% 90 day share price return and a very large 1 year total shareholder return, as investors weigh 10x Genomics’ clinical progress against concerns about revenue trends and the risks tied to past growth efforts. Spot opportunities across oncology-focused tools by scanning the hand picked 33 healthcare AI stocks, which, like 10x Genomics, tie advanced data-driven platforms to real clinical research use cases.\nBulls point to 10x Genomics’ fresh Fred Hutch tie up and recent 90 day surge, while bears focus on revenue worries and past losses. Which side does the current valuation actually support next? AdvertisementMost Popular Narrative: 7.7% Undervalued The most followed valuation storyline for 10x Genomics puts fair value at about $75.67, a touch above the last close at $69.86. That gap frames a debate where product momentum and AI related demand need to carry a lot of weight in the long term model.  The acquisition of Scale Biosciences broadens 10x Genomics' technical capabilities in single-cell analysis, allowing integration of foundational innovations like combinatorial indexing and quantum barcoding, which may accelerate innovation, reduce costs, and open up new high-value markets, positively impacting future revenue growth and margins.  See why 27 investors see 10x Genomics as 8% undervalued. Result: Fair Value of $75.67 (UNDERVALUED) Still, the story around 10x Genomics can change quickly if life science funding stays tight and product transitions keep pressuring pricing power and profitability. Find out about the key risks to this 10x Genomics narrative. Another View: Price-To-Sales Sends A Harsher Signal That 7.7% gap between 10x Genomics’ share price and the $75.67 fair value story looks modest. The P/S ratio tells a tougher story. At 14.8x sales, TXG trades at more than double US Life Sciences peers on 4.5x and far above its own 6.8x fair ratio, which may lift valuation risk if sentiment cools. Put simply, the current P/S suggests investors are paying a premium well beyond sector norms. If the market were to move back toward that 6.8x fair ratio, would the first valuation framework still feel as comfortable to you, or does this richer multiple change how much potential upside you see? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:TXG P/S Ratio as at Oct 2026Next Steps Mixed sentiment like this rarely stays neutral for long, so move quickly, review the full data set, and weigh both the upside potential and downside risk using the 1 key reward and 3 important warning signs. Looking for more investment ideas beyond 10x Genomics? If 10x Genomics has caught your attention, do not stop there. Broaden your watchlist now so you are not relying on a single story.  Target durable value by scanning a curated mix of quality opportunities through the 33 high quality undervalued stocks. Prioritise resilience and sleep better at night by reviewing companies with stronger financial footing using the list of solid balance sheet and fundamentals (25 results). Hunt for future standouts before they become crowded trades by checking the 20 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2676523936","isCrawlerRequest":true}